Development| Cancer Immunotherapy| Monoclonal Antibodies
Monoclonal Antibodies
One of the types of anticancer drugs are biotechnologically synthesized products—monoclonal antibodies (MAbs).

We have developed universal monoclonal antibodies for the treatment of tumor diseases:

• MAb against legumain (AEP), targeting a surface antigen of tumor cells that is overexpressed in more than 80% of tumors, including breast, colon, and pancreatic cancers, as well as central nervous system tumors.
• MAb against syndecan-1 (CD138), where the functional role of syndecan-1 in invasive tumor growth and metastasis is well established. The significance of these molecules in tumor cell survival has been proven, while their role in normal cell function across various tissues is minimal.

Advantages
The developed antibodies offer significant advantages including high antigen-binding affinity, low immunogenicity, and potent cytotoxicity, while being amenable to rapid large-scale production. Their universal applicability stems from the high-frequency expression of target molecules across diverse human tumor types.

The developed antibodies are humanized. These humanized antibodies demonstrate high-affinity binding to tumor-overexpressed legumain/syndecan-1, with the humanized design substantially reducing immunogenicity and enhancing patient tolerability.

The antibody architecture enables self-sufficient cytotoxic activity through both antibody-dependent and complement-dependent mechanisms, eliminating the need for additional cytotoxic agents. Furthermore, they exhibit antimetastatic properties by effectively blocking the C13 endopeptidase (legumain) activity.
АSafety and efficacy
The safety and efficacy profile stems from the monoclonal antibody molecule itself serving as the active pharmaceutical ingredient - a protein that ultimately degrades into amino acids, thereby eliminating any concerns regarding potential bioaccumulation or toxic degradation byproducts.

The safety, specificity, and therapeutic efficacy of these MAbs have been experimentally validated through comprehensive animal studies and in vivo models. The humanized antibodies demonstrate robust antitumor activity by not only inhibiting tumor proliferation and cellular migration but also facilitating the natural elimination of malignant cells through physiological clearance mechanisms.